507. Ketamine use disorder following intranasal esketamine for treatment-resistant depression: a case report and literature review
International Journal of Neuropsychopharmacology September 9, 2026 Y-H Chan, H-M Chang
Abstract Background Esketamine, the S-enantiomer of ketamine, is an NMDA receptor antagonist approved for treatment-resistant depression (TRD). Although regulated clinical trials suggest a low risk of misuse, concerns remain that esketamine exposure may facilitate transition to ketamine dependence, particularly in East Asia where illicit ketamine is widely available. Aims & Objectives To...